Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder

Postgraduate Medicine

Volumn 127, Issue 7, 2015, Pages 686-701

  Walker, Daniel J ^a   Mason, Oren ^b   Clemow, David B ^a   Day, Kathleen A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Attention MD   (United States)

Author keywords

Adult; Atomoxetine; Attention deficit hyperactivity disorder; Noradrenaline

Indexed keywords

ATOMOXETINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT;

ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; DECREASED APPETITE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; INSOMNIA; META ANALYSIS (TOPIC); NAUSEA; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); WORKING MEMORY; XEROSTOMIA; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR; COMPLICATION; DRUG EFFECTS; ETIOLOGY; EXECUTIVE FUNCTION; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATOMOXETINE HYDROCHLORIDE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIORAL SYMPTOMS; EXECUTIVE FUNCTION; HUMANS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84953342302     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2015.1081046     Document Type: Article

References (103)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942–8.
2. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716–23.
3. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402–9.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. Arlington: VA: American Psychiatric Publishing; 2013.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Arlington: VA: American Psychiatric Publishing; 2000.
6. Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, Doyle AE. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 2000;48:9–20.
7. Sobanski E, Bruggemann D, Alm B, Kern S, Deschner M, Schubert T, et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention- deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2007;257:371–7.
8. Sobanski E, Bruggemann D, Alm B, Kern S, Philipsen A, Schmalzried H, et al. Subtype differences in adults with attention- deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry 2008;23:142–9.
9. Able SL, Johnston JA, Adler LA, Swindle RW. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 2007;37:97–107.
10. Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. Med Gen Med 2006;8:12.
11. De Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. The prevalence and effects of adult attention- deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 2008;65:835–42.
12. Küpper T, Haavik J, Drexler H, Ramos-Quiroga JA, Wermelskirchen D, Prutz C, Schauble B. The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents. Int Arch Occup Environ Health 2012;85:837–47.
13. Meier NM, Perrig W, Koenig T. Neurophysiological correlates of delinquent behaviour in adult subjects with ADHD. Int J Psychophysiol 2012;84:1–16.
14. Edvinsson D, Bingefors K, Lindstrom E, Lewander T. ADHD- related symptoms among adults in out-patient psychiatry and female prison inmates as compared with the general population. Ups J Med Sci 2010;115:30–40.
15. Young S, Moss D, Sedgwick O, Fridman M, Hodgkins P. A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychol Med 2014;1–12.
16. Ludolph AG, Kolch M, Plener PL, Schulze UM, Spröber N, Fegert JM. [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD]. Z Kinder Jugendpsychiatr Psychother 2009;37:405–11.
17. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45:192–202.
18. Brod M, Pohlman B, Lasser R, Hodgkins P. Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study. Health Qual Life Outcomes 2012;10:47.
19. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue_ M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010;10:67.
20. Arnsten AF. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry 2011;69:e89–99.
21. Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry 2012;51:356–67.
22. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 2002;27: 699–711.
23. American Psychiatric Association. Highlights of Changes From DSM-IV-TR to DSM-5. Arlington: VA: American Psychiatric Publishing; 2013.
24. Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, et al. Atomoxetine treatment of attention-deficit/ hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebocontrolled clinical trial. J Clin Psychopharmacol 2013;33:45–54.
25. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53: 112–20.
26. Clemow DB. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients. Postgrad Med 2014;126:196–8.
27. Adler L, Dietrich A, Reimherr FW, Taylor LV, Sutton VK, Bakken R, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry 2006;18:107–13.
28. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, et al. Once-daily atomoxetine for adult attention-deficit/ hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009;29:44–50.
29. Goto T, Hirata Y, Takita Y, Trzepacz PT, Allen AJ, Song DH, et al. Efficacy and safety of atomoxetine hydrochloride in Asian adults with ADHD: A multinational 10-week randomized double-blind placebo-controlled Asian study. J Atten Disord 2013. [Epub ahead of print].
30. Johnson M, Cederlund M, Rastam M, Areskoug B, Gillberg C. Open-label trial of atomoxetine hydrochloride in adults with ADHD. J Atten Disord 2010;13:539–45.
31. Ni H-C, Lin YJ, Gau SS-F, Huang HC, Yang LK. An openlabel, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD. J Atten Disord 2013; Epub ahead of print.
32. Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P. A randomized, waiting listcontrolled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 2012;45:100–7.
33. Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, Tanaka Y. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci 2011;65:55–63.
34. Takahashi M, Goto T, Takita Y, Chung SK, Wang Y, Gau SS. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder. Asia Pac Psychiatry 2014;6:62–70.
35. Young JL, Sarkis E, Qiao M, Wietecha L. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebocontrolled trial. Clin Neuropharmacol 2011;34:51–60.
36. Sutherland SM, Adler LA, Chen C, Smith MD, Feltner DE. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry 2012;73:445–50.
37. Guo Y, Fijal B, Marshall S, Li G, Ahl J, Nisenbaum L, et al. Comparison of efficacy and safety between intermediate and extensive/ultra-rapid metabolizers of atomoxetine in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled maintenance of response clinical trial. Poster presented at The Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 5–9 March 2013, Indianapolis, IN.
38. Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008;12:248–53.
39. Adler LA, Spencer TJ, Levine LR, Ramsey JL, Tamura R, Kelsey D, et al. Functional outcomes in the treatment of adults with ADHD. J Atten Disord 2008;11:720–7.
40. Hirata Y, Goto T, Takita Y, Trzepacz PT, Allen AJ, Ichikawa H, Takahashi M. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. Asia Pac Psychiatry 2014;6:292–301.
41. Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE, Kondo D, et al. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. Atten Defic Hyperact Disord 2011;3:237–44.
42. Upadhyaya H, Ramos-Quiroga JA, Adler LA, Williams D, Tanaka Y, Lane JR, et al. Maintenance of response after openlabel treatment with atomoxetine in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: A placebo-controlled, randomised withdrawal study. Eur J Psychiatry 2013;27:185–205.
43. Block SL, Kelsey D, Coury D, Lewis D, Quintana H, Sutton V, et al. Once-daily atomoxetine for treating pediatric attention-deficit/ hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila) 2009;48:723–33.
44. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebocontrolled assessment. J Clin Psychopharmacol 2004;24:30–5.
45. Montoya A, Escobar R, Garcia-Polavieja MJ, Lachno DR, Alda JÁ, Artigas J, et al. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine. J Child Neurol 2011;26:31–6.
46. Leibowitz M, Ereshefsky L, Lin Q, Ledent E, Padich R, Allen AJ. Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects during clinically recommended dosing. Eur Neuropsychopharmacol 2005;15: S594–5.
47. Morris DW, Toups M, Trivedi MH. Measurement-based care in the treatment of clinical depression. Focus 2012;10:428–33.
48. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002;67:149–56.
49. Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008;95:140–6.
50. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002;111:279–89.
51. McCarthy S. Pharmacological interventions for ADHD: how do adolescent and adult patient beliefs and attitudes impact treatment adherence? Patient Prefer Adherence 2014;8:1317–27.
52. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol 2014;28:204–11.
53. Eli Lilly and Company. Strattera [US Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
54. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83.
55. Wietecha LA, Ruff DD, Allen AJ, Greenhill LL, Newcorn JH. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. J Clin Psychiatry 2013;74:1217–23.
56. Alatorre C, Kabul S, Montejano L, Kelsey D. Real world dosing patterns of atomoxetine in adults with attention-deficit/hyperactivity disorder. XVI Wold Congress of Psychiatry, Madrid, 2014.
57. del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011;69:e145–57.
58. Raiteri M, Del Carmine R, Bertollini A, Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol 1977;41:133–43.
59. Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998;71:274–80.
60. Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med 2014;126:64–81.
61. Shire US. Vyvanse [US Package Insert]. Wayne, PA: Shire, Inc; 2012.
62. Arias-Carrio_n O, Stamelou M, Murillo-Rodriguez E, Mene_ndez- González M, Pöppel E. Dopaminergic reward system: a short integrative review. Int Arch Med 2010;3:24.
63. Levy F. Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety. Neuropsychopharmacology 2004;29:1589–96.
64. Leckman JF, Peterson BS, Pauls DL. Tic disorders. In Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 2000.
65. Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009;26:212–21.
66. Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 2009;29:561–4.
67. Donnelly CL, Adler LA, Qiao M, Durell TM. Anxiety response to atomoxetine in patients with attention-deficit/hyperactivity disorder and comorbid anxiety. Poster presented at The 23rd Annual U.S.Psychiatric and Mental Health Congress (USPMHC), 18–21 November 2010, Orlando, FL.
68. Turner M, Wilding E, Cassidy E, Dommett EJ. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res 2013;243:28–37.
69. Gasior M, Bergman J, Kallman MJ, Paronis CA. Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology 2005;30:758–64.
70. Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend 2004;75:271–6.
71. Upadhyaya HP, Desaiah D, Schuh KJ, Bymaster FP, Kallman MJ, Clarke DO, et al. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention- deficit/hyperactivity disorder. Psychopharmacology (Berl) 2013;226:189–200.
72. Darredeau C, Barrett SP, Jardin B, Pihl RO. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol 2007;22:529–36.
73. Teter CJ, McCabe SE, Boyd CJ, Guthrie SK. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 2003;23:609–17.
74. Aldridge AP, Kroutil LA, Cowell AJ, Reeves DB, Van Brunt DL. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder. Pharmacoeconomics 2011;29:621–35.
75. [SAMHSA] Substance Abuse and Mental Health Services Administration. Treatment for Stimulant Use Disorders. Rockville: MD: Center for Substance Abuse Treatment, United States Department of Health and Human Services; 1999.
76. Carlson GA, Kelly KL. Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol 2003;13:137–42.
77. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008;96:145–54.
78. Wilens TE, Adler LA, Tanaka Y, Xiao F, D’Souza DN, Gutkin SW, Upadhyaya HP. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin 2011;27:2309–20.
79. Adler LA, Guida F, Irons S, Shaw D. Open-label pilot study of atomoxetine in adults with ADHD and substance use disorder. J Dual Diagnosis 2010;6:196–207.
80. Benegal V, Viswanath B, Narayanaswamy JC, Jose SP, Chakraborty V, Sankar D, et al. The efficacy of atomoxetine as adjunctive treatment for co-morbid substance use disorders and externalizing symptoms. Asian J Psychiatr 2013;6:544–7.
81. Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 2006;26:648–52.
82. Hirata Y, Goto T, Takita Y, Trzepacz PT, Allen AJ, Song DH, et al. Improvements of health-related QOL and executive functions of atomoxetine in Asian adults with ADHD: A multinational 10-week randomized,double-blind placebocontrolled Asian study. Int J Neuropsychopharmacol 2012;15:222.
83. Adler LA, Clemow DB, Williams DW, Durell TM. Atomoxetine effects on executive function as measured by the BRIEF-A in young adults with ADHD: a randomized, double-blind, placebocontrolled study. PLoS ONE 2014;9:e104175.
84. Adler L, Tanaka Y, Williams D, Trzepacz PT, Goto T, Allen AJ, et al. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. J Clin Psychopharmacol 2014;34:461–6.
85. Brown TE, Holdnack J, Saylor K, Adler L, Spencer T, Williams DW, et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord 2011;15: 130–8.
86. Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2013;16:1959–73.
87. Barkley RA, Anderson DL, Kruesi M. A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. J Atten Disord 2007;10:306–16.
88. Kay GG, Michaels MA, Pakull B. Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine. J Atten Disord 2009;12: 316–29.
89. Sobanski E, Sabljic D, Alm B, Dittmann RW, Wehmeier PM, Skopp G, Strohbeck-Kühner P. Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine. Eur Psychiatry 2013;28:379–85.
90. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007;46:242–51.
91. United States Food and Drug Administration. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Rockville: MD: United States Food and Drug Administration; 2009.
92. Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008;31: 345–54.
93. FDA Drug Safety Communication. Important safety label changes to cholesterol-lowering statin drug. 2014. Available from http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
94. Adler L, Wilens T, Zhang S, Durell T, Walker D, Schuh L, et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict 2009;18:393–401.
95. Camporeale A, Porsdal V, De Bruyckere K, Tanaka Y, Upadhyaya H, Deix C, Deberdt W. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials. J Psychopharmacol 2015;29:3–14.
96. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673–83.
97. Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, et al. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. PLoS One 2013;8:e52991.
98. Holick CN, Turnbull BR, Jones ME, Chaudhry S, Bangs ME, Seeger JD. Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol 2009;29:453–60.
99. Spiller HA, Hays HL, Aleguas A Jr. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 2013;27:531–43.
100. Kashani J, Ruha AM. Isolated atomoxetine overdose resulting in seizure. J Emerg Med 2007;32:175–8.
101. Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol 2014;24:426–34.
102. Camporeale A, Day KA, Ruff D, Arsenault J, Williams D, Kelsey DK. Profile of sexual and genitourinary treatmentemergent adverse events associated with atomoxetine treatment: a pooled analysis. Drug Saf 2013;36:663–71.
103. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995;152:1652–8.